Piper Sandler this year was a powerful reminder of how quickly the ground is shifting under our feet for life sciences & healthcare companies. As CEO of Clinakos Inc., I walked away with a few clear learnings that will shape my thinking for 2025 and beyond. 👇
Here are my biggest takeaways from four days in New York:
🚀 AI + data are now the baseline, not the headline. Nearly every serious conversation assumed AI was already in the stack. Both Marty Makary M.D., M.P.H. and Vinay Prasad, MD MPH emphasized the fact that Agentic AI is already deployed and in use by FDA reviewers. Any biotech and pharma company lacking the capability to deploy AI for patient-level data is taking a huge risk.
🔍 Data advantage is the new competitive moat. The organizations that stood out weren’t just “data rich”—they had integrated, longitudinal, clinically meaningful data that actually changed choices in R&D, trial design, and commercial strategy.
🧬 Real-world data must be actionable, not just observational. It’s no longer enough to describe what happened. The expectation is decision-grade insight: better patient stratification, more precise site selection, clearer signals for label expansion, and market access.
🧭 Leaders are reframing data as a strategic asset. The most compelling voices treated patient-level data like pipeline and capital—something that compounds in value when curated well, governed responsibly, and focused on patient impact.
For Clinakos, these conversations reinforced our conviction: staying obsessively focused on real patient journeys—and building data and AI solutions that truly serve them—is the surest way to create durable value for biopharma and, most importantly, for patients. 💙
👉 Follow Clinakos Inc.
